Evaluation of painful sensory symptoms in restless legs syndrome: Experience from two clinical trials

Sleep Medicine

Volumn 12, Issue 2, 2011, Pages 186-189

  Hornyak, Magdolna ^a   Sohr, Mandy ^b   Busse, Michael ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Outcome; Pain; Pramipexole; Randomized controlled trial; Restless legs syndrome; Treatment

Indexed keywords

PLACEBO; PRAMIPEXOLE;

ADULT; ARTICLE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; TREATMENT RESPONSE; UNPLEASANT SENSATION; VISUAL ANALOG SCALE;

ADULT; AGED; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79251645881     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2010.11.007     Document Type: Article

References (20)

1. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119. for the International Restless Legs Syndrome Study Group.
2. Bassetti C.L., Mauerhofer D., Gugger M., Mathis J., Hess C.W. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001, 45:67-74.
3. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
4. Michaud M., Lavigne G., Desautels A., Poirier G., Montplaisir J. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov Disord 2002, 17:112-115.
5. Bentley A.J., Rosman K.D., Mitchell D. Can the sensory symptoms of restless legs syndrome be assessed using a qualitative pain questionnaire?. Clin J Pain 2007, 23:62-66.
6. Oertel W.H., Trenkwalder C., Zucconi M., Benes H., Borreguero D.G., Bassetti C., et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007, 22(Suppl. 18):S466-S675.
7. Trenkwalder C., Hening W.A., Montagna P., Oertel W.H., Allen R.P., Walters A.S., et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008, 23:2267-2302.
8. Ferini-Strambi L., Aarskog D., Partinen M., Chaudhuri K.R., Sohr M., Verri D., et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double blind, placebo-controlled trial. Sleep Med 2008, 9:874-881.
9. A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75mg/day pramipexole (Sifrol®, Mirapexin®) orally for 12weeks to investigate the safety and efficacy in out-patients with idiopathic Restless Legs Syndrome associated with mood disturbances (BI 248.604). Available from: http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.604_U07-2329upload_new19148.pdf.
10. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4:121-132.
11. Jensen M.P., Karoly P. Self-report scales and procedures for assessing pain in adults. Handbook of pain assessment 1992, 135-151. The Guildford Press, New York. D.C. Turk, R. Melzack (Eds.).
12. Dworkin R.H., Turk D.C., Wyrwich K.W., Beaton D., Cleeland C.S., Farrar J.T., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008, 9:105-121.
13. Fulda S., Wetter T.C. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008, 131:902-917.
14. Stiasny-Kolster K., Magerl W., Oertel W.H., Moller J.C., Treede R.-D. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 2004, 127:773-782.
15. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008, 8:781-797.
16. Paulus W., Dowling P., Rijsman R., Stiasny-Kolster K., Trenkwalder C., de Weerd A. Pathophysiological concepts of restless legs syndrome. Mov Disord 2007, 22:1451-1456.
17. Connor J.R., Wang X.S., Allen R.P., Beard J.L., Wiesinger J.A., Felt B.T., et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009, 132:2403-2412.
18. Holman A.J., Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005, 52:2495-2505.
19. Tracey I., Mantyh P.W. The cerebral signature for pain perception and its modulation. Neuron 2007, 55:377-391.
20. Wiech K., Ploner M., Tracey I. Neurocognitive aspects of pain perception. Trends Cogn Sci 2008, 12:306-313.